PMID- 33319440
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 23
IP  - 4
DP  - 2021 Apr
TI  - Change in glucose-lowering medication regimens in individuals with type 2 
      diabetes mellitus during the COVID-19 pandemic in Germany.
PG  - 910-915
LID - 10.1111/dom.14293 [doi]
AB  - AIM: To estimate the proportion of individuals with type 2 diabetes mellitus 
      (T2DM) undergoing changes in glucose-lowering therapy in 2019 and 2020. METHOD: 
      Individuals with T2DM who had at least one consultation in one of 940 general 
      (including diabetologist) practices in Germany between January and July 2019 (N = 
      79 268) and between January and July 2020 (N = 85 046) were included. Therapy 
      changes were defined as the prescription of new glucose-lowering drugs, with or 
      without the discontinuation of previous treatments (therapy switch and add-on 
      therapy, respectively). The number of T2DM patients with at least one medication 
      regimen change was calculated for the periods 1 January to 14 March in 2019 and 
      2020, and for the periods 15 March to 31 July in 2019 and 2020. March 2020 
      corresponded to the beginning of the lockdown in Germany. RESULTS: Overall, there 
      was a decrease in the number of patients with at least one medication regimen 
      change in the period 15 March to 31 July 2019 compared with 15 March to 31 July 
      2020 (dipeptidyl peptidase-4 inhibitors: -15%; sodium-glucose co-transporter-2 
      inhibitors: -3%; glucagon-like peptide-1 receptor agonists: 0%; other oral 
      glucose-lowering drugs: -6%; and insulin: -21%). CONCLUSIONS: The coronavirus 
      disease-2019 (COVID-2019) pandemic had a strong impact on glucose-lowering drug 
      use in T2DM patients in Germany. More research is warranted to further 
      investigate the treatment and management of T2DM individuals during the COVID-19 
      era in Germany and elsewhere.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Jacob, Louis
AU  - Jacob L
AUID- ORCID: 0000-0003-1071-1239
AD  - Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
AD  - Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, 
      Montigny-le-Bretonneux, France.
FAU - Rickwood, Sarah
AU  - Rickwood S
AD  - IQVIA, London, UK.
FAU - Rathmann, Wolfgang
AU  - Rathmann W
AD  - German Diabetes Center, Institute for Biometrics and Epidemiology, Duesseldorf, 
      Germany.
FAU - Kostev, Karel
AU  - Kostev K
AUID- ORCID: 0000-0002-2124-7227
AD  - Epidemiology, IQVIA, Frankfurt, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210104
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *COVID-19
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Substitution/trends
MH  - Drug Therapy, Combination/trends
MH  - Female
MH  - Germany
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - SARS-CoV-2
MH  - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Germany
OT  - coronavirus disease-2019
OT  - glucose-lowering medication
OT  - pandemic
OT  - regimen change
OT  - type 2 diabetes mellitus
EDAT- 2020/12/16 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/12/15 06:09
PHST- 2020/12/06 00:00 [revised]
PHST- 2020/11/10 00:00 [received]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/12/15 06:09 [entrez]
AID - 10.1111/dom.14293 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2021 Apr;23(4):910-915. doi: 10.1111/dom.14293. Epub 2021 
      Jan 4.